Kurin, Inc. Announces Agreement with Premier for Kurin Lock® to help impact contaminated blood cultures

Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that it has been awarded a Med/Surg Group agreement in the Safety Phlebotomy Category with Premier. Effective December 1, 2018 the new three-year agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the Kurin blood culture products.

“Premier and Kurin share patient safety values by providing innovative solutions designed to address a common source of contaminated blood cultures and in doing so reducing overall healthcare costs,” said Bob Rogers, Inventor and CEO of Kurin. “We are pleased to be the only blood diversion product on contract with Premier and are already engaged with Premier hospitals to help impact patient care and positively impact hospitals financially.”

Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,000 U.S. hospitals and 165,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.

About Kurin, Inc.
Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.


About the Author